What is the purpose of PREA (Pediatric Research Equity Act) in drug development?

• A. To require pediatric assessments for new drugs when appropriate
• B. To expedite orphan drug approval
• C. To regulate dietary supplements
• D. To extend patent life for pediatric medications

Answer: (A)

The main idea behind PREA is to ensure that when new drugs are developed, there is an obligation to assess how the drug works in children and whether pediatric labeling is needed. Sponsors must include a plan to study safety and efficacy in pediatric populations and submit pediatric data as part of the drug approval process, unless a waiver or deferral is granted by the FDA. This addresses the fact that children are not just small adults—their pharmacokinetics and pharmacodynamics can differ, and dosing or safety information for kids is often lacking without targeted studies. The goal is to provide appropriate use information for pediatric patients and improve dosing, safety, and effectiveness in children.

This focus is not about expediting orphan drug approvals, regulating dietary supplements, or extending patent life. It specifically targets ensuring that pediatric considerations are integrated into the development and labeling of new drugs.